Contact this trialFirst, we need to learn more about you.
JAK Inhibitor
Peritransplant Ruxolitinib for Myelofibrosis
Recruiting1 awardPhase 2
Seattle, Washington
This trial is testing whether a drug can help prevent a condition where the transplanted cells from a donor can attack the body's normal cells and improve transplant outcomes in patients with primary and secondary myelofibrosis.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.